Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases

A method for increasing expression of ApoA-I in a mammal comprising administering a therapeutically effective amount of a compound of Formula I:

• or a pharmaceutically acceptable salt thereof wherein:
• X is selected from CR11, and N;
• Y is selected from CR12, and N;
• R3 and R8 are each hydroxyl;
• R11 and R12 are each independently selected from alkoxy, aryloxy, alkenyl, amino, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, ketone, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone;
• R1, R5, R6, and R10 are each independently selected from alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydrogen, hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone;
• R2, R4, R7, and R9, are each independently selected from aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydrogen, hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone, or
• two adjacent substituents selected from R1, R2, R4, R5, R6, R7, R9, R10, R11, and R12 are connected in a 5 or 6-membered ring to form a bicyclic aryl or bicyclic heteroaryl;
• each W is independently selected from C and N;
• and
• Z is a double bond;
• provided that:
• R2 and R4 are not each hydroxyl;
• at least one W is N;
• when W is N, then p is 0;
• and
• when W is C, then p is 1